Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Characteristics of Individuals with Post-Stroke Epilepsy who Do Not Respond to Monotherapy
Cerebrovascular Disease and Interventional Neurology
Cerebrovascular Disease and Interventional Neurology Posters (7:00 AM-5:00 PM)
202
To identify the potential risk factors and characteristics of individuals with post-stroke epilepsy who do not respond to anti-epileptic drug monotherapy.

Literature suggests the incidence of post-stroke epilepsy (PSE) may be as high as 20% and accounts for approximately 50% of new-onset epilepsy among adults over the age of 65. Current clinical practice supports the use of anti-epileptic drugs (AEDs) following a second epileptic event. Patients tend to respond well to monotherapy; however, literature has reported anywhere from <5% to 46% of patients with PSE may experience seizure recurrence. Risk-factors and common characteristics among individuals who develop epilepsy while receiving monotherapy remain unclear.  
We performed a retrospective analysis of University of Utah Health electronic medical records from January 2000 to October 2020. Patients with ICD codes for stroke and seizure or epilepsy were included in our original cohort. Our final analysis will include patients with a diagnosis of stroke who have had at least two documented epileptic events after stroke onset confirmed by a neurologist. 
Our primary dataset consisted of 2033 patients with a mean (SD) age of 68.5 (18.1) years, 55% of which were female. Patients who suffered either ischemic or hemorrhagic stroke and had a diagnosis of PSE confirmed by a neurologist were included in our final cohort. The following are recorded: date of stroke onset, date of epilepsy onset, comorbid medical conditions, AED prescribed, concomitant medications prescribed, recurrent epileptic seizures, NIHSS, smoking status, and basic demographic data.

Patients with PSE who experience recurrent epileptic seizures despite monotherapy represent a unique subset of individuals. As we continue to analyze data, we plan to report on characteristics of individuals who develop subsequent epileptic seizures despite receiving AED monotherapy. This analysis may aid in predicting which patients may have a better prognosis or, conversely, require more intensive therapy and monitoring.
Authors/Disclosures
Cecilia Peterson
PRESENTER 		An immediate family member of Ms. Peterson has received personal compensation for serving as an employee of 100Plus.
Nazanin Sheibani, MD (Tremont) Dr. Sheibani has nothing to disclose.
Ka-Ho Wong (U of U Neurology Clinic) The institution of Mr. Wong has received research support from The Sumaira Foundation . The institution of Mr. Wong has received research support from The Siegel Rare Neuroimmune Association.
Varsha Muddasani, MBBS (Einstein Medical Center) Dr. Muddasani has nothing to disclose.
Kaitlin McLean Kaitlin McLean has nothing to disclose.
Lilly Fagatele (University of Utah Neurology) Ms. fagatele has nothing to disclose.
Amir M. Arain, MD, FÂ鶹´«Ã½Ó³»­ (University of Utah) Dr. Arain has nothing to disclose.
Blake Newman, MD (University of Utah) Dr. Newman has nothing to disclose.
Adam De Havenon, MD, FÂ鶹´«Ã½Ó³»­ (Yale University) Dr. De Havenon has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novo Nordisk. Dr. De Havenon has or had stock in Certus.Dr. De Havenon has or had stock in TitinKM. The institution of Dr. De Havenon has received research support from NIH/NINDS. Dr. De Havenon has received publishing royalties from a publication relating to health care.